Abstract
In general, the invention relates to pharmaceutical compositions comprising (R)-oxybutynin and a norepinephrine reuptake inhibitor (NRI) and methods of treating Sleep Apnea comprising administering (R)-oxybutynin and a norepinephrine reuptake inhibitor (NRI). In some embodiments, the NRI is atomoxetine.
Full Text
What is claimed is:
In general, the invention relates to pharmaceutical compositions comprising (R)-oxybutynin and a norepinephrine reuptake inhibitor (NRI) and methods of treating Sleep Apnea comprising administering (R)-oxybutynin and a norepinephrine reuptake inhibitor (NRI). In some embodiments, the NRI is atomoxetine.
Timeline
Filed
05/20/2026Published
09/17/2026Granted
Not AvailableIPC Codes(4)
A61K 31/138:Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K 31/165; pindolol A61K 31/404; timolol A61K 31/5377)
A61K 31/216:of acids having aromatic rings, e.g. benactizyne, clofibrate
A61K 45/06:Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca